Acute Coronary Syndromes
Commentary
Are Beta-Blockers Needed Post MI? No, Even After the ABYSS Trial
ABYSS is consistent with REDUCE-AMI, says doctor; stopping beta-blockers at 1 year did not increase death, MI, or stroke.
Latest News
Setbacks Identified After Stopping Beta-Blockers
Though halting beta-blockers does not increase stroke, death, or MI, CV hospitalization rates, BP, and HR were increased.
Latest News
A Racing Heart Signals Trouble in Chronic Kidney Disease
The risk for cardiovascular events was higher in patients with a heart rate of 80-89 beats/min than in those with a heart rate < 70 beats/min...
Latest News
Xanthelasma Not Linked to Heart Diseases, Study Finds
Lipid profiles were similar between the two groups, with no difference in total cholesterol, high- and low-density lipoprotein, and triglyceride...
Commentary
Did Statin Decision-Making Just Get Harder?
I am not disturbed by the PREVENT score. Clinicians treat individuals, not populations.
Commentary
On Second Thought: The Truth About Beta-Blockers
Yes, beta-blockers are useful pills, and they are standard of care, just maybe not for post-MI patients with normal ejection fractions because...
Latest News
Fruits and Vegetables May Promote Kidney and Cardiovascular Health in Hypertensive Patients
Adults with chronic kidney disease and hypertension showed slower disease progression with a low-acid diet.
Commentary
Avoid These Common Mistakes in Treating Hyperkalemia
Often, patients end up following a potassium-restricted diet for long periods because they aren’t told the cause of their hyperkalemia.
Latest News
Diabetes-Related Outcomes and Costs Have Mostly Improved
After adjustments, mortality per 1000 person-years decreased by 28% from 2002 to 2020, with the largest risk reduction, 63%, in acute myocardial...
Latest News
Flu May Increase MI Risk Sixfold, More If No CVD History
Flu may increase risk for MI short term, especially for patients with no CV disease, study confirms.
Latest News
Trial of Impella Heart Pump Stopped
After another trial of the heart pump showed better survival, RECOVER IV trial was halted.